- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03123874
Milk in Life Conditions (MiLC): Bacterial Composition of Human Milk Pumped and Stored in "Real-Life" Conditions (MiLC)
Milk in Life Conditions (MiLC): Characterizing the Bacterial Composition of Human Milk Pumped and Stored in "Real-life" Conditions
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Participants will donate 1 oz of human milk during each of two consecutive pumping sessions, for a total volume of 2 oz donated on one day. To collect this human milk, participants will be asked to fully express one breast during each pumping session. Participants will pump once with the participant's own pump set-up and once with the sterile pump set-up (provided by the research team). Women will be randomized to which pump is used first.
Randomization will be done using stratified randomization as follows: participants were stratified by how their infants were fed, namely whether infants were fed human milk only vs. human milk and complementary foods). Then, randomization was conducted within each strata. The researchers aim to have a minimum of 25 participants in each stratum.
All human milk collections will occur at participants' homes between 0700 and 1100 hours. The second pumping session must begin 3 hours (+/-30 minutes) after the beginning of the first pumping session (e.g. the first pumping session at 7:30 am and the second at 10:30 am). Participants will elect from which breast to donate human milk and that breast will be used for both pumping sessions. Participants will be asked not to nurse from or pump that breast during the 2 hours before the first pumping session and not until after the second pumping session (a total of ~5.5 hours).
From the milk produced during each pumping session (which could be up to ~6 oz), researchers will collect 1 oz using a sterile, plastic syringe. Participants will keep the remaining volume of milk. Each ounce of milk collected will be separated into 5 sterile containers (provided). Participants will store donated milk at home until it is picked up by a researcher 2, 4, and 30 days after pumping.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
New York
-
Ithaca, New York, Forente stater, 14853
- Hay Laboratory, B75C Wing Hall, Cornell University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Lactating women over the age of 18 years
- Self-reported as healthy women and infants
- Use an electric breast pump
- Confident of ability to donate 1 oz of milk from one breast during each of two consecutive pumping sessions where pumping sessions are 3 hours (+/- 30 minutes) apart and between 0700-1100 hours.
- Able to store donated milk at home for 30 days
- Have infants who do not consume formula or only consume formula episodically as long as the most recent formula-feeding occurred > 2 weeks before the day milk is pumped for this study.
Exclusion Criteria:
- Not confident of ability to donate 1 oz of milk from one breast during each of two consecutive pumping sessions, 3 hours (+/- 30 minutes) apart and between the hours of 0700-1100 hours.
- Infant consumption of formula in the past 2 weeks
- Current indication of breast infection (e.g., breast pain, discomfort, lumps, mastitis with fever, red streaks, or hard red portions of the breast)
- Breast pain that the woman does not consider "normal" for lactation/breastfeeding
- Signs/symptoms of acute illness in woman or infant in past 7 days including fever (rectal or temporal temperature ≥99.5 F), dark green nasal discharge, diarrhea (abrupt onset of 3 or more excessively "loose" stools in one day), vomiting (where infant vomiting is not associated with feeding), or severe cough.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Sterile pump set-up first
Participants will pump with sterile pump set-ups first.
Approximately 3 hours later, participants will pump with their own pump set-ups.
|
Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
|
|
Eksperimentell: Mother's Own pump set-up first
Participants will pump with their own pump set-ups first.
Approximately 3 hours later, participants will pump with sterile pump set-ups.
|
Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Bacterial Community Richness
Tidsramme: 0 days after pumping
|
Richness is the total number of different bacterial taxa detected in the sample.
This metric will be assessed on data collected via high-throughput sequencing of the bacterial 16S rRNA gene present in milk.
|
0 days after pumping
|
|
Bacterial Community Diversity
Tidsramme: 0 days after pumping
|
Bacterial community diversity will be assessed using the the Shannon diversity index.
The Shannon diversity index is a type of entropy measure and is a function of the distribution of the total number of organisms across all of the species.
If S is the total number of species in the sample and p_i is the number of organisms in the i-th species divided by the total number of organisms, then Diversity = -Σ p_i log(p_i).
This metric will be assessed on data collected via high-throughput sequencing of the bacterial 16S rRNA gene present in milk.
|
0 days after pumping
|
|
Total Live Aerobic Bacterial Counts
Tidsramme: 0 days after pumping
|
Number of live total aerobic bacteria in milk assessed by aerobic culturing of milk on plate count agar.
Reported as colony-forming units (CFU)/mL.
|
0 days after pumping
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Kathleen M. Rasmussen, ScD, Cornell University
- Hovedetterforsker: Anthony Hay, PhD, Cornell University
- Studieleder: Sarah Reyes, MS, Cornell University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB #: 1608006566
- 2T32DK007158-42 (U.S. NIH-stipend/kontrakt)
- NYC-399436 (Annet stipend/finansieringsnummer: NIFA/USDA)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Bakteriell vekst
-
Yonsei UniversityFullførtFibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Reseptors (FGFRs) Genetisk avvik gastrisk kreft, INCB054828, PaclitaxelKorea, Republikken
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.FullførtAvansert brystkreft | HER2 forsterket | Human Epidermal Growth Factor Receptor 2 (HER2)Forente stater, Belgia, Canada, Italia, Spania, Storbritannia
-
Reshma L. Mahtani, D.O.Gilead SciencesRekrutteringBrystkreft | Avansert brystkreft | Metastatisk brystkreft | Hormonreseptor-positiv brystkreft | Human Epidermal Growth Factor 2 Lav brystkreftForente stater
-
Xinhua Hospital, Shanghai Jiao Tong University...RekrutteringFetal Growth Restriction (FGR)Kina
-
Xinhua Hospital, Shanghai Jiao Tong University...Påmelding etter invitasjonFetal Growth Restriction (FGR)Kina
-
Assistance Publique - Hôpitaux de ParisRekrutteringIntrauterin vekstbegrensning | Fetal Growth Restriction (FGR)Frankrike
-
University of British ColumbiaAvsluttetIntrauterin vekstrestriksjon (IUGR) | Fetal Growth Restriction (FGR)Canada
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaFullførtFetal Growth Restriction (FGR)Italia
-
Carey Anders, M.D.PfizerAktiv, ikke rekrutterendeAvansert brystkreft | Hjernemetastaser | Human Epidermal Growth Factor 2 Positivt brystkarsinomForente stater
-
University of OxfordRekrutteringSvangerskap | Svangerskapsforgiftning | Svangerskapsdiabetes mellitus (GDM) | Fetal Growth Restriction (FGR) | Placenta | Graviditetsindusert hypertensjon (PIH)Storbritannia